Withdrawals due to adverse events · people with dermatomyositis and polymyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · boys with DMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · people with mitochondrial myopathy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · people with myotonic dystrophy type 1
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · people with dermatomyositis and polymyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · people with myotonic dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · children and adolescents with juvenile dermatomyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes adverse effects ‐ any adverse effect compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
POLYPEPTIDE ‐ CERULETIDE showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · patients with antipsychotic‐induced tardive dyskinesia
ANTIEPILEPTIC ‐ LEVETIRACETAM showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Allergic adverse events · chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse effects ‐ not reported · women having elective vaginal hysterectomy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects Skin/local reactions · patients with Old World cutaneous leishmaniasis
It is very uncertain whether paromomycin ointment changes adverse effects Skin/local reactions compared with vehicle (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ dystonia · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ dystonia compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Adverse effects of the interventions · Nursing home residents (mean age 78.3 to 86.0 years; more than 66% women; 62.1% to 87.3% with dental prostheses)
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Clinically important adverse effects · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found